2020 Annual Meeting - American Association for the Study of Liver Diseases (AASLD) — ASTRO Joint Session on the Multidisciplinary Management of Hepatocellular Carcinoma: Guidelines, Practicalities and a Tumor Board
Liver cancer incidence is growing faster than any other cancer in men and women. It is evident that the optimal care of patients with HCC necessitates the involvement of a multidisciplinary team utilizing evidence-based cancer guidelines. The American Association for the Study of Liver Diseases (AASLD) Guidelines for the Treatment of HCC serves as the benchmark synoptic guideline for the best evidence-based management of HCC, with NCCN guidelines for HCC adapted from the AASLD guidelines. In this joint AASLD-ASTRO educational session, attendees will gain an appreciation for the AASLD guidelines on the optimal multidisciplinary management for patients with non-metastatic HCC. For clinical scenarios where the data for optimal liver-directed or surgical therapy is conflicted, attendees will hear from a multidisciplinary panel consisting of interventional radiology, hepatology, surgery and interventional radiology on best approaches, perils and pitfalls.
Target Audience
The activity is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, diagnostic radiologists, specialists, and radiation oncology residents.
Learning Objectives
- Determine the necessity of a multidisciplinary team in the management of HCC and the expertise each brings to the optimal care of the patient.
- Differentiate clinical scenarios where AASLD guidelines have clear recommendations on optimal therapies for the management of HCC.
- Nima Nabavizadeh, MD is employed at Oregon Health & Science University and has no financial relationships with a commercial interest.
- Scott Naugler, MD is employed at Oregon Health & Science University and has no financial relationships with a commercial interest.
- Sravana K. Chennupati, MD is employed at Alta Bates Comprehensive Cancer Center, Sutter Health and has no financial relationships with a commercial interest.
- Prasoon Mohan, MD is employed at University of Miami Health System and has no financial relationships with a commercial interest.
- Parsia Vagefi, MD is employed at University of Texas, Southwestern and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
Price
Policies:
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.